Go Back

Hypofractionation in Breast Cancer Radiotherapy

About the Presentation

This seminar on hypofractionation in breast will cover the following areas:

  • What is hypofractionation?
  • Why might this be useful?
  • What is the benefit in breast cancer?
  • What are the concerns regarding hypofractionation?
  • Future directions of hypofractionation / unanswered questions?

On completing this seminar participants should:

  • Appreciate the clinical utility of hypofractionation in breast cancer;
  • Be aware of the clinical evidence for the usage of hypofractionation in breast cancer treatment;
  • Be aware of the concerns regarding hypofractionation in breast cancer radiotherapy;
  • Know the various hypofractionation dose / fractionation regimens.

About the Author

Dr Gerry Hanna

Dr Gerry Hanna is Consultant Clinical Oncologist and Senior Lecturer at the Centre for Cancer Research and Cell Biology, Queen’s University of Belfast. He is involved in the treatment of lung and breast cancer, both with systemic therapy and radiation therapy. He completed a PhD fellowship in 2010 on the topic of PET/CT for target volume delineation in the radiotherapy planning process for patients with lung cancer. In addition to PET/CT for radiation treatment planning his research interests include the use of IMRT in lung cancer, stereotactic radiotherapy for lung cancer, altered fractionation in breast cancer and the use of predictive assays.


Presentation's slides